Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (401-410 of 412) with videos related to

Pageof 42
Sort By:
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trialRoshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Cancer Research Communications|November 18, 2025
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor PatientsVivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, et al.
Journal for Immunotherapy of Cancer|March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Nature Medicine|January 19, 2023
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A Yap, Naval Daver, Mikhila Mahendra, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2023
Operational Ontology for Oncology (O3): A Professional Society-Based, Multistakeholder, Consensus-Driven Informatics Standard Supporting Clinical and Research Use of Real-World Data From Patients Treated for CancerCharles S Mayo, Mary U Feng, Kristy K Brock, et al.
Pageof 42

Showing results (401-410 of 412) with videos related to

Sort By:
Pageof 42
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trialRoshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Cancer Research Communications|November 18, 2025
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor PatientsVivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, et al.
Journal for Immunotherapy of Cancer|March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.
The New England Journal of Medicine|February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and ChildrenAlexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Nature Medicine|January 19, 2023
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A Yap, Naval Daver, Mikhila Mahendra, et al.
International Journal of Radiation Oncology, Biology, Physics|May 27, 2023
Operational Ontology for Oncology (O3): A Professional Society-Based, Multistakeholder, Consensus-Driven Informatics Standard Supporting Clinical and Research Use of Real-World Data From Patients Treated for CancerCharles S Mayo, Mary U Feng, Kristy K Brock, et al.
Pageof 42